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Abstract
Background: Even though early dietary management of phenylketonuria (PKU) successfully prevents severe
neurological impairments, deficits in cognitive functioning are still observed. These deficits are believed to be the
result of elevated levels of phenylalanine throughout life. Research on cognitive functioning in adults with PKU
(AwPKU) often focuses on domains shown to be compromised in children with PKU, such as attention and
executive functions, whereas other cognitive domains have received less attention. This systematic review aimed to
provide an overview of cognitive functioning across domains examined in early treated (ET) AwPKU.
Methods: A systematic search was performed in Ovid MEDLINE(R), PsycINFO, Web of Science, Cochrane, Scopus,
Embase, ScienceDirect, and PubMed for observational studies on cognitive performance in ET AwPKU.
Results: Twenty-two peer-reviewed publications, reporting on outcomes from 16 studies were reviewed.
Collectively, the results most consistently showed deficits in vigilance, working memory and motor skills. Deficits in
other cognitive domains were less consistently observed or were understudied. Furthermore, despite reports of
several associations between cognitive performance and phenylalanine (Phe) levels throughout life the relationship
remains unclear. Inconsistencies in findings across studies could be explained by the highly heterogeneous nature
of study samples, resulting in large inter- and intra-variability in Phe levels, as well as the use of a variety of tests
across cognitive domains, which differ in sensitivity. The long-term cognitive outcomes of early and continuous
management of PKU remain unclear.
Conclusions: To better understand the development of cognitive deficits in ET AwPKU, future research would
benefit from 1) (inter)national multicentre-studies; 2) more homogeneous study samples; 3) the inclusion of other
nutritional measures that might influence cognitive functioning (e.g. Phe fluctuations, Phe:Tyrosine ratio and
micronutrients such as vitamin B12); and 4) careful selection of appropriate cognitive tests.
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Background
Phenylketonuria (PKU) is a rare (on average 1 in 10.000–
12.000 live births in Western Europe) inborn error of
metabolism. It is characterised by reduced activity of the
hepatic enzyme phenylalanine hydroxylase (PAH), caused
by mutations in the encoding gene [1]. To date, around
1044 PAH-gene variants have been documented [2]. PAH
is responsible for the conversion of phenylalanine (Phe) to
tyrosine (Tyr). Reduced PAH activity results in elevated
Phe levels, decreased Tyr levels and an altered Phe:Tyr
ratio in individuals with PKU [1]. When left untreated,
PKU can cause severe and irreversible neurological
impairments [3].
Since its discovery, research into PKU has improved
diagnosis and management of the disorder immensely.
Patients are diagnosed via new-born screening [4] and,
generally, treatment is started as early as possible. Treat-
ment is aimed at keeping Phe levels low [5], but guide-
lines (target phenylalanine levels) vary between countries
[6]. Despite developments of novel treatment strategies
i.e. Sapropterin dihydrochloride (Kuvan) and Pegvaliase
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(Palynzig), the conventional treatment for PKU is still a
diet low in protein supplemented with mixtures of free
amino acids (other than Phe), vitamins, minerals, trace el-
ements, and essential fatty acids lacking in the low-protein
diet [7].
With treatment, severe cognitive impairments are pre-
vented [1]. Nonetheless, deficits in cognitive functioning
in PKU patients are still observed. In childhood, deficits
are mainly observed in executive functions (EF), such as
working memory (WM) and reasoning/planning, atten-
tion, and processing speed [8, 9]. In adults, similar
deficits have been reported [10]. However, the majority
of research has focussed on these specific cognitive do-
mains, whereas other cognitive functions have received
less attention. There is a lack of a comprehensive and
systematic overview of cognitive functioning across
different cognitive domains in early treated adults with
PKU (ET AwPKU) assessing the effectiveness of conven-
tional treatment strategies [11].
There is some debate on the specific neuropsycho-
logical mechanism(s) responsible for the observed cogni-
tive deficits in PKU, but the general belief is that these
deficits are related to patients’ Phe-levels at several
stages throughout life (e.g. concurrent Phe levels, life-
time Phe levels, variation in Phe levels, altered Phe:Tyr ra-
tio) [12]. Two theories on the mechanism of action of the
disturbed Phe metabolism in PKU have been developed.
The first suggests that, because Phe competes with other
Large Neutral Amino Acids (LNAA; e.g. Tryptophan
(Trp) and Tyr) for transport across the blood-brain barrier
(BBB), high levels of Phe saturate the LNAA-transporters.
As a result, PKU patients often present with lower brain
concentrations of other LNAA and important neurotrans-
mitters serotonin, norepinephrine and dopamine [13, 14],
known to be involved in cognitive functioning [15].
Furthermore, it has been suggested that high brain Phe
concentrations cause neurotoxicity, which is thought to
interfere with cerebral protein synthesis, increase mye-
lin turnover, and inhibit neurotransmitter synthesis
[16]. In addition to uncertainties about the exact
mechanism underlying suboptimal cognitive function-
ing, it is unclear whether observed deficits in EFs are
the consequence of reduced speed of processing or
whether impairments in speed of processing are the
consequence of deficits of EF [17].
The overall management of PKU is complex, not only
requiring adherence to the PKU diet and Phe-free pro-
tein substitute but also requiring regular collection of
blood samples, recording of food intake and regular
visits to the metabolic clinic [18]. Adherence to the diet
and protein substitutes is thought to be especially crucial
during the early childhood years since research has
shown that cognitive outcomes are closely related to the
control of blood phenylalanine levels in this period of
life [19, 20], and should be maintained through adult-
hood to protect from neuropsychological dysfunction
[21–24]. However, the strict low-protein diet imposes a
burden on patients and their families and has been
associated with dietary non-adherence, especially in ado-
lescents and young adults [22, 25–28]. Various metabolic
centres have reported increased loss to follow-up and
decreased adherence to dietary recommendations when
patients grow older [27, 29, 30]. As a consequence, and
because ‘diet for life’ is still relatively recent advice [31],
the majority of ET AwPKU that have participated in re-
search have discontinued their diet and Phe-free protein
substitutes at some point in their lives. Thus very few
people with PKU will truly be early and continuously
treated, and the impact of such treatment breaks on
cognitive function is not known.
This systematic review aims to provide a clear overview
of cognitive functioning in ET AwPKU by addressing the
following questions: (1) Which cognitive domains are
affected in ET AwPKU; (2) How are cognitive outcomes
across different domains related to concurrent and life-
time Phe levels in ET AwPKU; and (3) are there any
differences in cognitive performance between early and
continuously treated (ECT) AwPKU and ET AwPKU who
discontinued their diet and/or Phe-free protein substitutes
at some point?
Methods
This systematic review followed the preferred reporting
items for systematic reviews and meta-analyses
(PRISMA) 2009 checklist and is registered in PROS-
PERO. The registration number is CRD42016043706
[14].
Search strategy and search terms
Searches of electronic databases were carried out on 31
July 2017. This search was updated on 2 March 2018
and again on 18 June 2018. Databases searched were
Ovid MEDLINE(R), PsycINFO, Web of Science,
Cochrane, Scopus, Embase, ScienceDirect, and PubMed
1953 to June 2018. The following search terms were
used: (‘phenylketonuria’ OR ‘PKU’) AND (‘cogniti*’ OR
‘memory’ OR ‘attention’ OR ‘visual-spatial’ OR ‘visuo--
spatial’ OR ‘recall’ OR ‘recognition’ OR ‘problem solving’
OR ‘reaction time’ OR ‘vigilance’ OR ‘executive func-
tion*’ OR ‘reasoning’ OR ‘psychomotor’ OR ‘motor’ OR
‘processing’ OR ‘planning’ OR ‘verbal fluency’ OR
‘inhibit*’).
Furthermore, the reference lists of existing reviews
and identified articles were examined individually to
supplement the electronic search. A total of 10,803 ci-
tations were screened against inclusion and exclusion
criteria.
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Inclusion and exclusion criteria
This review was limited to articles published in
peer-reviewed journals in English, Dutch or German.
Case reports, abstracts and conference proceedings were
not included. Papers were included or excluded in this
review using the following criteria.
Participants
Studies of ET AwPKU aged 18 years and over of either
gender were included. As treatment guidelines vary world-
wide, age at the start of treatment for the ET AwPKU
sample of each paper was included in the data extraction,
where available. Animal studies were excluded. Studies
where results of ET AwPKU were not reported separately
(e.g. papers reporting combined outcomes of ET adoles-
cent and adult PKU patients) were excluded from this
review.
Intervention
Papers reporting on a sample of ET AwPKU patients
who had been treated with the conventional low-protein
diet with Phe-free protein substitutes were included.
Studies reporting on cognitive outcomes in ET AwPKU
as a result of (an acute) manipulation of Phe-levels or
additional supplementation with Tyr, or vitamins and
minerals were excluded. Finally, as this systematic review
aims to give a clear overview of the efficacy of early
treatment on cognitive outcomes in adulthood, interven-
tions with new treatments such as Sapropterin dihy-
drochloride (Kuvan) and Pegvaliase (Palynzig), which
were not available when the ET AwPKU commenced
their treatment, were excluded.
Control(s)
Research including a healthy control group or a com-
parator group (e.g. diabetic patients, autistic patients)
was included. Papers without a specific control group
(e.g. comparison to standardized or normative data)
were also included.
Outcome measures
Studies including any objective measure of cognitive
performance were included. Metabolic outcomes (e.g.
concurrent Phe levels) were not a requirement for in-
clusion but were considered where available.
Design
Observational studies (i.e. cross-sectional, cohort, case-con-
trol and longitudinal studies) were included in this
systematic review.
Study selection process
The literature search yielded a total of 10,803 citations.
Following removal of 6287 duplicates, a total of 4516
citations were retrieved for possible inclusion in the
review. The titles and abstracts of these citations were
screened by one reviewer (DH) to remove obviously ir-
relevant reports (n = 4371), resulting in retention of 145
papers. Another reviewer (CC) independently screened,
at random, 5% of the titles and abstracts to establish
agreement about the inclusion and exclusion of studies.
The inter-rater agreement was 95%, and any disagree-
ments during this process were resolved by discussion,
and a consensus decision was reached. The full-text
versions of the remaining 145 articles were retrieved and
examined for eligibility based on the inclusion criteria,
and authors were contacted to clarify any missing
information. Inter-rater agreement was 100%. As a
result of the screening process, a further 123 articles
were excluded. A total of 16 studies reported in the
remaining 22 articles were included in the review
(see Fig. 1).
Quality assessment
The quality of all included papers was assessed using the
‘quality assessment tool for reviewing studies with di-
verse design’ (QATSDD) [32]. Two reviewers (DH and
CC) independently awarded each research paper quality
scores by assessing each QATSDD criterion (for example
‘Description of procedure for data collection’) on a
4-point scale from 0 to 3 (0 = the criterion is not at all
described, 1 = described to some extent, 2 =moderately
described and 3 = described in full). The sum of scores
of all relevant QATSDD criteria reflects the overall qual-
ity of each paper. The scores, expressed as a percentage
of the maximum possible score of 42, are included in
the data extraction table (Additional file 1: Table S1).
Quality ratings ranged from 35.7 to 59.5% of the max-
imum score and overall average quality was rated at
48.3%. Papers scored particularly low with respect to
reporting of statistics: there was no clear evi.dence of
sample size considered in terms of analysis, justification
for analytical method selected or assessment of reliability
of the analytical process across publications. Publications
scored particularly high on the following criteria: explicit
theoretical framework, statement of aims/objectives, and
description of procedure for data collection. Finally,
whilst most papers had strong discussions in terms of
interpretation and implications of the data, they lacked a
critical discussion of the strengths and weaknesses of the
studies reported.
Data extraction
The Cochrane data extraction form was modified for the
purposes of this review. Data were extracted into the
standardised form by one researcher (DH), and authors
were contacted when insufficient information was pro-
vided in the published paper. Half (50%) of these articles
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were then double data extracted by another researcher
(CC). Any disagreements were resolved by discussion,
and a consensus decision was reached.
Results
Selected studies
Twenty-two articles reporting on outcomes from 16
observational studies assessing cognitive functioning in
ET AwPKU were included in this review.
Fourteen studies included healthy controls, often
matched for gender and age, and (less often) IQ and
socio-economic status. The two remaining studies com-
pared the performance of ET AwPKU on cognitive tasks
to either standardized [33] or normative data [34].
Four studies reported on a group of in ET AwPKU who
had discontinued their diet [35–38], three of these also in-
cluded ET AwPKU who were on diet but reported results
for on- and off-diet patients separately [36–38]. Further-
more, four studies described their sample of AwPKU as
early and continuously treated (ECT) [36, 39–45]. However,
the upper range of Phe levels at the time of testing of all
ECT AwPKU samples exceeded upper target treatment
levels. All other research included a mixed sample of both
on-diet ET AwPKU and ET AwPKU who were either
off-diet or following a relaxed diet in their study samples.
Seven publications compared effects of high versus low
Phe levels [33, 34, 40, 46–49]. However, all of these studies
used different cut-off Phe levels for their high and low Phe
groups: Bik-Multanowski et al. [34] compared cognitive
performance of ET AwPKU with concurrent levels of
≤720 μmol/L and > 720 μmol/L; Brumm et al. [33] used
cut-off Phe levels of < 1000 μmol/L and > 1000 μmol/L at
the time of testing; Jahja et al. [40] compared effects of
concurrent, childhood, adolescent and lifetime Phe by
comparing low and high Phe groups according to the most
frequently used upper target treatment level during child-
hood, 360 μmol/L (low: < 360 μmol/L, high: ≥360 μmol/L);
Bartus et al. [48], de Felice et al. [47] and Nardecchia et al.
[49] compared cognitive functioning of patients with Phe
levels below and above 600 μmol/L, a frequently used
upper target treatment level during adolescence and
adulthood [50]; additionally, Bartus et al. [48] compared
cognitive task performance of ET AwPKU with average
childhood (0–12 years) Phe below and above 360μmo/L;
and, finally, Romani et al. [46] divided their sample into
two equally large subgroups based on their adulthood Phe
levels (low: < 650 μmol/L, high: > 950 μmol/L), noting that
Fig. 1 Flow diagram of the study selection process
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their ET AwPKU group with good metabolic control (low
Phe group) had adulthood Phe levels close to current treat-
ment guidelines in the UK (< 700 μmol/L [51]).
The majority of publications (18 reporting results of
14 different studies) looked at correlations between
cognitive performance and Phe levels during various
periods and at various points throughout life.
Finally, three studies reported on a longer-term follow-
up study of ET AwPKU [42, 49, 52]. Two of these com-
pared cognitive outcomes during childhood with cognitive
outcomes in the same sample in adulthood [42, 49]. The
third followed ETAwPKU over a 5-year period [52].
Included studies, with details of the cognitive tasks
and metabolic measures utilised, as well as the reported
results are summarised in (Additional file 1: Table S1).
Table 1 summarises impairments observed in outcome
measures of cognitive functioning, and Additional file 2:
Table S2 provides reported correlations between Phe
and Tyr levels across the life-span and outcome measures
cognitive function. Finally, Table 2 provides an overview of
different tasks used across different cognitive domains in
the studies included in this review. It shows the frequency
of use of each of the tasks across all included studies, as
well as their sensitivity in ET AwPKU.
Cognitive outcomes in ET AwPKU: Overview of reported
results
The following section provides an overview of cognitive
outcomes in ET AwPKU. Where possible, outcomes in
adulthood are compared with outcomes in the same
sample during childhood [42, 49].
As can be seen in (Additional file 1: Tables S1) and
Table 2, a large number of different cognitive tasks were
used, spanning various cognitive domains. Furthermore,
some discrepancy between papers exists with regards to
the domains that cognitive tasks are ascribed to. For the
purpose of this review, cognitive outcomes are cate-
gorised according to their cognitive domains. There are
many different conceptualisations regarding how differ-
ent cognitive tasks associate with one another and with
particular cognitive domains. The framework used for
the current review was adapted from a commonly used
approach to understanding and measuring cognitive
domains [53]. For a description of cognitive domains,
subdomains and examples of tests reflecting each do-
main as applied to the studies reported in this review,
see Galioto et al. [54]. Note, however, that Galioto et al.
[54] describe verbal fluency as a function of language,
whereas this review follows Lezak et al. [53]‘s original
framework, classifying it as an EF. Additional file 1:
Table S1 summarises cognitive outcomes as reported
in the papers included in this review. In Tables 1, 2
and Additional file 2: Table S2, outcomes have been
re-categorised in line with the framework used here.
Attention and processing speed
Attentional capacity
Healthy controls outperformed ET AwPKU on the ma-
jority of measures of attentional capacity used across
several studies included in this review [11, 33, 36, 45].
However, it was found that ET AwPKU were often
slower, but not less accurate, than controls [11, 36]. Fur-
thermore, Channon et al. [36] observed differences in
accuracy between off- and on-diet ET AwPKU, with the
off-diet group making more errors compared to the
on-diet group. Using an aggregate score for performance
on attention tasks included in their study, Romani et al.
[46] reported that the ET AwPKU with low adult Phe
levels significantly outperformed the high-Phe group.
Bik-Multanowski et al. [34] and Brumm et al. [33] found
no differences in performance ET AwPKU with high
compared to low concurrent Phe levels.
The relationship between performance on tasks
reflecting attentional capacity and measures of metabolic
control was assessed in seven studies. Only two of these
reported a relationship between concurrent Phe and
measures of attentional capacity [36, 55]. However, the
observed correlations were not in the expected direction,
suggesting that attentional capacity was better with
higher concurrent levels of Phe. Several papers reported
significant correlations with metabolic control during
childhood [33, 36, 46], adulthood [17, 45] as well as
throughout life [46], with the majority (n = 10/11, see
Additional file 2: Table S2) suggesting lower Phe levels
were associated with better task performance. However,
no correlations between adolescent Phe levels and atten-
tional capacity were reported. Furthermore, the correla-
tions observed by Channon et al. [36] were limited to
measures of speed, with no correlations for accuracy.
Vigilance/focus
Compared to healthy controls, ET AwPKU have con-
sistently been found to show impairment on measures
of vigilance/focus [11, 37, 40, 45, 52]. In one study,
however, this impairment was only observed in older
(> 32 years old) ET AwPKU [52]. Brumm et al. [33]
reported no group deficit on a continuous perform-
ance task (CPT) when comparing number of omission
errors of ET AwPKU with normative data, but did
find that ET AwPKU with high concurrent Phe per-
formed significantly worse than those with low con-
current Phe. This is in line with results reported by
Bik-Multanowski et al. [34] and Romani et al. [46],
although observed differences in performance of the
low and high Phe groups in the latter study failed to
reach significance.
Observed associations between measures of metabolic
control and vigilance in ET AwPKU are somewhat in-
consistent but suggest childhood Phe levels are not
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Table 2 Overview of tasks used to assess cognitive functioning in ET AwPKU across different cognitive domains
Cognitive domain Taska Sensitivityb
Attention and processing speed
Attentional capacity California Verbal Learning Test (CVLT) – List A trial 1 [33] 1/1
Choice Reaction Time [11, 34] 1/2c
Conjoined Search [11] 1/1c
Detection with Distractors [11] 0/1
Digit Span Forward (WAIS-R) [33] 0/1
Feature Search [11] 1/1c
n-back (0-back and 1-back trials) [36] 1/1c
Stroop colour [11, 33] 2/2c
Stroop word [33] 0/1
Telephone Search Test (TEA) [45] 1/1
Video tracking [55] 1/1
9/13
Vigilance/focus Continuous Performance Test (CPT) – omission errors [33] 0/1
Rapid Visual Processing [11, 34] 2/2
Sustained Attention Dots (ANT) [40]
Dot Pattern Exercise (SVAT) [37]
2/2
Telephone Search Test with Counting (TEA) [45] 1/1
Test d2 [52] 1/1d
6/7
Processing speed CPT – response rate [33] 0/1
Motor Screening Test – latency [48] 0/1
Saccadic Latency [38] 1/1e
Simple Detection [11]
Simple Reaction Time (CANTAB) [34]
Finger Motor Speed Exercise (SVAT) [37]
0/3
Stockings of Cambridge – initial thinking time [48] 0/1
Trail Making Test-A [1, 2, 33, 52]
Attention Diagnostic Method [56]
2/3
WAIS-III (Processing Speed Index) [35] 1/1e
4/11
Executive functions
Complex executive functions Brixton Test [45] 0/1
Elithorn Perceptual Maze Test [49] 1/1
Object alternation learning [36] 0/1
Set Shifting Visual (ANT) [42] 1/1f
Six Elements Test [45] 0/1
Spatial Working Memory – Strategy [48] 1/1
Stockings of Cambridge [48] 1/1
Tower of Hanoi [11]
Tower of London [49]
1/2
Trail Making Test (TMT) B-A [11, 33, 35] 0/3
WAIS-III (Perceptual Organisation Index) [35] 1/1e
Wisconsin Card Sorting Test (WCST) [11, 33, 49, 56] 3/4
9/17
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Table 2 Overview of tasks used to assess cognitive functioning in ET AwPKU across different cognitive domains (Continued)
Cognitive domain Taska Sensitivityb
Inhibitory control CPT [33] 1/1
Flanker [36, 42] 1/2c
Go-nogo [44] 0/1
Set Shifting Visual (ANT) [42] 0/1
Stop Signal Task [34] 1/1
Stroop (interference) [11, 33] 0/2
Sustained Attention Dots (ANT) [40] 1/1
4/9
Working memory Corsi Block Tapping Test [11] 0/1
CVLT – perseverative error [33] 1/1
Digit Span – backward [11, 33] 2/2
Feature Integration (ANT) [40] 1/1
Letter Pattern Exercise (SVAT) [37] 0/1
Memory Search 2 Dimensional (ANT) [40] 1/1
n-back (2-back trials) [36] 1/1c
Non-word Repetition [11] 1/1
Self-Ordered Pointing test [45] 1/1
Spatial Span [34] 1/1
Spatial Working Memory [34, 48] 2/2
Visuo-Spatial Sequencing (ANT) [40] 1/1
WAIS-III (Working Memory Index) [35] 0/1
12/15
Verbal fluency Animal naming [11, 33] 2/2
Controlled Oral Word Association
Test [33, 35]
1/2
Letter fluency [11, 45] 1/2
4/6
Language
Basic language skills: semantic processing Boston Naming Test [33]
Picture naming [11]
1/2
Blocked cyclic naming [47] 0/1
Emotional Prosody Discrimination test [47] 0/1
Hayling Sentence Completion Test – Part A [47] 0/1
Narrative production: Recalling the
Cinderella story [47]
0/1
Non-emotional Prosody Discrimination
test [47]
0/1
Peabody Picture Vocabulary Test –
Revised (PPVT-R) [33]
0/1
Word reading [11] 1/1c
Word spelling [11] 0/1
2/10
Complex language skills Appreciation of Humour test [47] 0/1
Blocked cyclic naming – semantic
Inference [47]
0/1
Comprehension of Inferred Meaning test [47] 1/1c
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Table 2 Overview of tasks used to assess cognitive functioning in ET AwPKU across different cognitive domains (Continued)
Cognitive domain Taska Sensitivityb
Conflicting prosody – attend to prosody test [47] 0/1
Hayling Sentence Completion Test – Part B [45, 47] 1/2
Metaphor Picture test [47] 1/1c
Naming: semantic inference [11] 0/1
Narrative production: Recalling the Cinderella story [47] 1/1
Non-word reading [11] 1/1c
Non-word spelling [11] 0/1
Phoneme deletion [11] 0/1
Similarities (WAIS-R/WASI) [11, 33] 1/2
Spoonerisms [11] 0/1
Vocabulary (WAIS-R/WASI) [11, 33] 0/2
WAIS-III (Verbal Comprehension Index) [35] 0/1
Perceptual judgement task [36] 0/1
6/19
Memory and learning
Immediate recall: verbal / visual CVLT – List A trial 5 and trials 1–5 [33] 1/1
Paired Associates Verbal Learning – trial 1–5 [11] 0/1
Paired Associates Visual Learning [11] 0/1
Rey Auditory Verbal Learning Test (RAVLT) – Trial A1-A5 [11] 0/1
ROCFT – Immediate recall [49] 0/1
WMS-III [35] 0/1
1/6
Delayed recall: verbal / visual CVLT – Sort delayed recall and Long delayed recall [33] 1/1
Paired Associates Verbal Learning – delayed [11] 0/1
RAVLT – Delayed recall [11, 45] and retention [11] 0/2
ROCFT – Delayed recall [33, 45] 0/2
WMS-III [35] 0/1
1/7
Recognition: verbal / visual CVLT – Recognition memory [33] 0/1
Delayed Matching to a Sample [11] 0/1
RAVLT – Recognition [45] 0/1
ROCFT – Recognition [45] 0/1
WMS-III [35] 0/1
0/5
Motor skills Digit Symbol (Substitution) Task [11, 33] 1/2
Grooved Pegboard [11, 33] 1/2
MLS [55] 1/1
Motor Screening Test – errors [48] 1/1
Pursuit (ANT) [42] 1/1f
5/6
Social-cognitive abilities Face Recognition (ANT) [41] 1/1g
Faux-Pas Recognition Test [41] 1/1h
Identification of Facial Emotions (ANT) [41] 1/1g
Reading the Mind in the Eyes Task [41] 1/1h
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related to vigilance in ET AwPKU, whereas significant
negative correlations with adult Phe have been found.
Inconsistent results have been reported for concurrent,
adolescent and lifetime Phe levels. Jahja et al. [42] and
Romani et al. [46] reported significant correlations
between concurrent Phe and measures of vigilance,
whereas Brumm et al. [33] did not. Romani et al. [46]
also reported a significant association between vigilance
and metabolic control during adolescence. However, this
was not observed by Weglage et al. [52]. Finally, Romani
et al. [46] found a significant correlation between an
aggregated score of measures of vigilance and lifetime
Phe, whereas Jahja et al. [42] reported no significant
associations between the two.
Processing speed
It has been suggested that observed cognitive deficits in
ET AwPKU could be due to a deficit in information pro-
cessing in these patients. It is not uncommon for ET
AwPKU to be slower, but not less accurate on various
measures spanning different cognitive domains. Romani
et al. [17] investigated processing speed in ET AwPKU.
Their results suggest that ET AwPKU do not suffer from
an overarching deficit in speed of processing, but rather
that reduced speed of performance on tasks across mul-
tiple cognitive domains could be the result of slower or
more cautious executive decision-making processes [17].
In line with their findings, performance of ET AwPKU
on ‘pure’ processing speed outcome measures, such as
simple reaction time, was not generally impaired in the
studies included in this review. Compared to controls, ET
AwPKU demonstrated slower reaction times on approxi-
mately half of the processing speed measures reported in
studies included in this review [35, 38, 52, 56]. In two of
these studies, these deficits were observed in a group of
ET AwPKU who had discontinued dietary treatment [35,
38]. In another study, the impairment in information pro-
cessing was only found for older (> 32 years) ET AwPKU
[52]. However, four of the studies included in this review
reported no impairments in performance on measures of
processing speed in either on or off-diet ET AwPKU
[11, 33, 37, 48]. When comparing groups of ET
AwPKU with different levels of metabolic control, Brumm
et al. [33] reported that ET AwPKU with high concurrent
Phe levels were significantly slower than those with low
concurrent Phe levels, whereas Bik-Multanowski et al.
[34] and Bartus et al. [48] found no differences between
patients with good versus poor concurrent and childhood
(between 0 and 12 years) metabolic control.
Five studies investigated associations between simple
measures of processing speed and measures of metabolic
control. Brumm et al. [33] and Bartus et al. [48] ob-
served no correlations, whereas Weglage et al. [52]
reported negative correlations with Phe levels during
childhood, adolescence and young adulthood. Further-
more, two studies reported a relationship between speed
of processing and concurrent Phe levels, but the direc-
tion was inconsistent: one study reported a negative
relationship [38] while the other reported a positive rela-
tionship [56]. Significant correlations were generally
more frequently observed with measures of speed com-
pared with measures of accuracy.
Executive functions
Complex executive functions
Although reasoning and planning, flexibility (set-shift-
ing/switching), organisation, monitoring and rule finding
are separate executive functions (EF), several of the
cognitive tasks used in the studies reported here concur-
rently engage more than one EF and are often reported
as measures of complex EF, higher order EF, or “multi--
tasking”. Reported findings across studies suggest a con-
trast between performance on tasks that require
different levels of planning/reasoning and flexibility, with
deficits in ET AwPKU being more pronounced in tasks
requiring more planning/reasoning and flexibility. For
example, deficits in performance on the Wisconsin Card
Sorting Test (WCST) were reported by Brumm et al.
[33], Nardecchia et al. [49] and Palermo et al. [11], but
not by Ris et al. [56]. Furthermore, Bartus et al. [48]
reported that controls outperformed ET AwPKU on
measures of problem solving (Stockings of Cambridge
Table 2 Overview of tasks used to assess cognitive functioning in ET AwPKU across different cognitive domains (Continued)
Cognitive domain Taska Sensitivityb
4/4
Visual-spatial abilities Block design (WAIS-R) [33] 0/1
Picture arrangement (WAIS-R) [33] 0/1
Picture completion (WAIS-R) [33] 0/1
ROCFT – with copy/initial copy [33, 45, 49, 56] 2/4
2/7
a Number of observed impairments in task performance in ET AwPKU / frequency of us; b (−sub measure) if task relates to multiple cognitive domains); c Compared
to controls, ET AwPKU differed in speed (slower), not accuracy; d Only for older (>32) ET AwPKU;
e Only for off-diet ET AwPKU; f High-high ET AwPKU group worse performance than low-high PKU group (no controls included in analysis); g Effect disappeared after
adding age as a covariate; h Effect disappeared after including IQ as a covariate
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of the Cambridge Neuropsychological Test Automated
Battery (CANTAB)) and strategy (Spatial Working Memory
(CANTAB)), whereas Channon et al. [45] and Nardecchia
et al. [49] did not observe any deficits in performance on
the Brixton task or Elithorn Perceptual Maze Test respect-
ively. Some of the reported impairments in complex EF
were only observed for ET AwPKU with poor metabolic
control throughout childhood [42, 48] or off-diet ET
AwPKU [35]. However, although ET AwPKU with lower
concurrent Phe-levels showed better performance on com-
plex EF tasks, none of the studies reported significant
differences between ET AwPKU with good versus poor
concurrent metabolic control [33, 46, 48].
Relationships with metabolic control throughout life
and complex EF were observed, but better metabolic
control during adolescence seems to be the strongest in-
dicator of better complex EF during adulthood [46, 49].
Reported correlations between concurrent Phe and com-
plex EF were not in the expected direction, suggesting
ET AwPKU with higher concurrent levels of Phe per-
formed better on complex EF tasks than those with
better metabolic control at the time of testing [35].
Inhibitory control
The majority of the studies that included measures of in-
hibitory control did not reveal any significant impair-
ments in inhibition in ET AwPKU compared to controls
[11, 40, 42, 44], although the PKU group tended to be
slower, not less accurate, than the control group in one
of the studies included in this review [36]. The
PKU-COBESO study was the only study to report ET
AwPKU were both significantly less accurate and slower
compared to controls [40]. Moyle et al. [44] observed a
similar trend in a smaller sample of ET AwPKU but
failed to find any significant differences. Based on nor-
mative data available for measures included in their
study, Brumm et al. [33] reported that ET AwPKU per-
formed below expectation (see Additional file 1: Table
S1) on several (CPT, Digit Span backwards and WCST),
but not all (Stroop, Trail Making Task part B), measures
of inhibitory control. However, they observed no signifi-
cant differences in performance between ET AwPKU
with good and poor concurrent metabolic control on
any of the tasks. Similarly, a recent study found no
significant differences in task performance between ET
AwPKU with low and high concurrent Phe levels [46].
In contrast, Bik-Multanowski et al. [34] reported signifi-
cant differences in performance on the CANTAB
Stop-Signal Task between ET AwPKU with good and
poor metabolic control, with the ET AwPKU with poor
metabolic control showing worse performance.
After splitting their ET AwPKU sample into high and
low Phe groups, Jahja et al. [40] reported that, compared
to controls, only ET AwPKU with high lifetime Phe
levels were slower and less accurate on an inhibitory
control task. Furthermore, their results showed that con-
current Phe was positively associated with reaction
times, but no correlations between childhood, adoles-
cent, adult or lifetime Phe levels and accuracy or speed
were found. Romani et al. [46] observed no correlations
between measures of inhibition and any of the measures
of metabolic control included in their research.
Working memory
Studies investigating performance of ET AwPKU on
WM or short-term memory (STM) tasks showed contra-
dictory findings [11, 33–37, 40, 45, 48].
In terms of accuracy, the majority of studies reported
that ET AwPKU made significantly more errors compared
to controls or normative data [11, 33, 34, 42, 45, 48]. In
contrast, the remaining three studies, two of which in-
cluded off-diet ET AwPKU, did not find significant differ-
ences in accuracy on WM tasks between ET AwPKU and
healthy controls [35–37]. Even though they did not ob-
serve any differences between ET AwPKU and controls,
Channon et al. [36] reported that off-diet ETAwPKU were
significantly less accurate on the n-back task than on-diet
ET AwPKU. Again, roughly half of the papers reporting
measures of speed found that both on-diet and off-diet ET
AwPKU were significantly slower than healthy controls
[36, 40]. Jahja et al. [40] observed a significantly greater
decline in speed with increasing WM load on two of their
measures, whereas other studies did not [35, 36].
When exploring relationships between WM and meta-
bolic control, Channon et al. [45] reported poor per-
formance on WM tasks was related to high concurrent
and average recent (year preceding testing) Phe levels as
well as elevated Phe levels between the ages of 21 and
28 years. In another study, despite not showing any sig-
nificant deficits in WM in on-diet and off-diet ET
AwPKU, speed on the 2-back task was found to be re-
lated to Phe levels between the ages of 13–16 years [36].
In the PKU-COBESO study [40], ET AwPKU were divided
into low- and high-Phe groups based on concurrent as
well as average childhood, adolescence, adult and lifetime
Phe levels. In line with findings of Bik-Multanowski et al.
[34], results showed that higher concurrent Phe levels re-
sulted in slower speed on two of the three WM tasks used
in this study (Feature Integration (FI) and Memory
Search 2-Dimensional (MS2D) of the Amsterdam
Neurological Tasks (ANT) battery). Additionally, life-
time Phe levels were positively related to the number
of errors made on tasks with a high WM load. Fur-
thermore, analyses revealed that ET AwPKU with high
average childhood Phe levels were significantly less
accurate than controls on two of three WM tasks
(Visuo-Spatial Sequencing (VSS) and FI). They were also
significantly less accurate on the FI task compared to ET
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AwPKU with low childhood Phe levels. Finally, ET
AwPKU with high childhood and lifetime Phe levels were
found to be significantly slower than controls on the
MS2D task. Romani et al. [46] did not find any significant
relationships between WM performance and concurrent
Phe or averages and variations of childhood, adolescent,
adult and lifetime Phe levels, but reported that the group
with low concurrent Phe levels outperformed the
high-Phe group. Bartus et al. [48] did not find any signifi-
cant differences in accuracy on the SWM (CANTAB) task
between on-diet ET AwPKU and those on a “loose diet”,
but did show that ET AwPKU with better metabolic con-
trol during childhood made less errors than those with
poorer control.
There does not seem to be a clear association be-
tween measures of WM and measures of metabolic
control: the majority of studies observed no relation-
ships, with the exception of some correlations found
with concurrent Phe and Phe at different stages of life
(see Additional file 2: Table S2) [33, 36, 40, 45].
Verbal fluency
Verbal fluency refers to the ability to orally produce
words that either fit into a specific category (category or
semantic fluency) or start with a specific letter (letter or
phonemic fluency). It has been suggested that language
processing is the critical component of verbal fluency
[57]. However, because verbal fluency tasks involve a
planned, systematic search of the lexicon, they are often
regarded as measures of EF [53]. Four studies in-
cluded in this review assessed verbal fluency in ET
AwPKU [11, 33, 35, 45]. Letter fluency was reported
to be impaired by Brumm et al. (2004) and Channon
et al. [45], but not Palermo et al. [11]. Palermo et al.
[11] did, however, find deficits in category fluency, as
did Brumm et al. [33]. In contrast, Moyle et al. [35]
found no deficits in either category or letter fluency
in a small sample of off-diet ET AwPKU. There was
no clear evidence for associations between metabolic
control and verbal fluency abilities in ET AwPKU.
Language (semantic processing)
Measures of semantic processing assess comprehension
of language as well as speed of retrieval of information
[53, 54]. Examples of semantic processing tasks include
expressive and receptive vocabulary, expressive naming
(spoken language), as well as measures of spelling and
reading (orthographic language). Five studies assessed
language processing in ET AwPKU. In contrast to
Brumm et al. [33], Palermo et al. [11] and de Felice et al.
[47] found no deficits on a basic picture naming task. In
line with this, apart from a reduction in speed of word
reading [11], no issues in basic language skills, including
receptive vocabulary, as well as measures of prosody,
reading and spelling without inference were observed in
ET AwPKU [11, 33, 47]. Performance of ET AwPKU on
complex language tasks, requiring EF such as planning,
inhibition and reasoning, has been inconsistent (see
Table 2). Most studies reported no deficits [33, 35, 36],
but impaired performance has been observed on several,
but not all, complex language tasks included in two
studies [11, 47]. When measures of accuracy and speed
have been reported separately, it appears that ET
AwPKU are slower but not less accurate on tasks that
suggest impaired complex language processing [11, 47].
With respect to the impact of Phe, Romani et al. [46]
found significant correlations between a composite
measure of the spoken language tasks used in their study
(picture and colour naming and both WASI verbal sub-
tests) and fluctuations in Phe as well as overall metabolic
control, but not average Phe levels, across the lifespan.
No correlations were found between any metabolic mea-
sures and performance on tasks assessing orthographic
language. Furthermore, ET AwPKU with better meta-
bolic control during adulthood performed better on all
language tests, but these differences were only significant
for measures of spoken language. However, no signifi-
cant differences in composite measures of spoken or
orthographic language were observed between groups of
ET AwPKU with high versus low concurrent Phe levels
[46]. Brumm et al. [33] reported that performance on
spoken language tasks (expressive naming, expressive
vocabulary and receptive vocabulary, but not the similarities
subtest of the Wechsler Adult Intelligence Scale-Revised
(WAIS-R)) was better in ET AwPKU with better metabolic
control at the time of testing and that performance on these
measures was negatively correlated with blood Phe levels
across the lifespan. De Felice et al. [47] found no associa-
tions between measures of metabolic control and any of
the language processing measures administered and, more-
over, reported no significant differences in performance be-
tween ETAwPKU with low versus high average Phe levels.
Memory and learning
The majority of studies assessing verbal and visual im-
mediate recall, delayed recall, or recognition memory in
both on-diet and off-diet ET AwPKU did not report any
impairments in ET AwPKU [11, 23, 45, 49]. However,
Romani et al. [46] reported that despite not finding any
significant differences between ET AwPKU and controls
on individual tasks of memory and learning, ET AwPKU
seemed to perform marginally worse across tasks when
the scores were aggregated [46]. Furthermore, they reported
that their lower-Phe group outperformed their higher-Phe
group. In contrast, Brumm et al. [33] reported cognitive im-
pairments in immediate, short-term and long-term verbal
and visual delayed recall, but did not report any significant
differences in memory task performance between ET
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AwPKU with high or low concurrent Phe levels. In their
study, immediate and delayed verbal and visual recall were
found to be negatively correlated with median Phe levels
between the ages of 5.5 and 6 years [33]. Romani et al.
[46] reported negative correlations between aggregated
memory and learning scores and concurrent Phe as well
as average Phe and variation of Phe levels across the life-
span. Other studies found no correlations between per-
formance on memory tasks and any of the metabolic
measures included [23, 45, 49].
Motor skills
Results of assessments of motor skills are mixed but sug-
gest an impairment in ET AwPKU [11, 33, 42, 48, 55].
Using a battery of 7 tests to assess fine motor abilities,
Pietz et al. [55] reported deficits in steadiness (tremor),
dexterity and speed, but not visuomotor abilities. None of
the observed deficits appeared to correlate significantly
with any of their indices of metabolic control. Jahja et al.
[42] found that ET AwPKU with low average Phe levels
during childhood were better at a motor task that involved
continuous monitoring of task performance (following a
randomly moving target) than those who had high average
childhood Phe levels. They reported significant correla-
tions between task performance and childhood Phe levels
[42]. Palermo et al. [11] also observed significant deficits
in ET AwPKU on two tasks (Digit Symbol Substitution
Task (DSST) and Grooved Pegboard) assessing visuo-
motor coordination and, using a composite measure, re-
ported that ET AwPKU with low concurrent Phe levels
outperformed those with high levels at the time of testing.
Furthermore, they reported significant correlations be-
tween a composite score of both tasks and concurrent
Phe, childhood Phe variation and average levels, and ado-
lescent, adult and lifelong Phe variation as well as overall
metabolic control [46]. Using the same two tasks, Brumm
et al. [33] did not find any deficits in ET AwPKU but did
report that ET AwPKU with low Phe levels at the time of
testing outperformed those with high concurrent Phe
levels on the DSST. Finally, Bartus et al. [48] reported sig-
nificant differences in accuracy on the CANTAB Motor
Screening Test (MOT) between ET AwPKU and controls,
with controls outperforming the ET AwPKU, but did not
report any differences between ET AwPKU with good ver-
sus poor metabolic control during childhood (0–12 years)
or at the time of testing. Both Brumm et al. [33] and
Bartus et al. [48] did not find any associations between
visuomotor coordination and any of the metabolic out-
comes included in their studies.
Social-cognitive abilities
“Social cognition involves all mental processes that
underlie social interactions and comprises the ability to
perceive, to interpret and to respond appropriately to
social cues” ([40], p., 356). Examples of social-cognitive
abilities include the ability to recognise faces and identify
emotions [41]. Only one study to date has assessed
social-cognitive abilities in ET AwPKU [41]. ET AwPKU
performed worse than controls on all four tasks included
in the research. When controlling for age, impairments
in ET AwPKU were only observed on two of the tasks.
When IQ was taken into account, no significant differ-
ences between ET AwPKU and controls were reported.
No significant associations between social-cognitive out-
comes and concurrent or lifetime measures of metabolic
control were found.
Visual-spatial abilities
Measures of visual-spatial abilities reflect planning,
reasoning, memory and motor skills. Using the ‘with
copy’ subtest of the Rey Österrieth Complex Figure Test
(ROCFT), two studies reported impairments in a mixed
sample of on- and off-diet ET AwPKU [33, 56], whereas
two other studies did not [45, 49]. Furthermore, Brumm
et al. [33] found no impairments on visual-spatial sub-
tests of the WAIS-R (Block Design, Picture Arrangement
and Picture Completion) and no difference in perform-
ance between ET AwPKU with high versus low concur-
rent Phe levels on any of the visual-spatial measures
included in their study. They did, however, observe
negative correlations between performance on two of
the WAIS-R subtests (Block Design and Picture Com-
pletion) and median Phe levels between the ages of 5.5–
6 and 9.5–10 years. Other studies did not observe any
associations between visual-spatial abilities and measures
of metabolic control [49, 56].
Cognitive outcomes in early treated adults with PKU (ET
AwPKU): Long-term follow-up
Two studies included in this review were long-term
follow-up studies of a cohort of ET AwPKU who partici-
pated in research during their childhood: Nardecchia et
al. [49] assessed cognitive functioning of 14 ET AwPKU
previously examined by Leuzzi et al. [58]. Jahja et al. [42]
tested 21 of 69 ET AwPKU (48 of the original sample
were lost to follow-up (69%)) who had previously been
involved in the study by Huijbregts et al. [59–61]. Both
follow-up studies were conducted approximately 14 years
after the original research and found that cognitive per-
formance across a range of tests, mainly assessing EF, ei-
ther remained stable or improved [42, 49]. Nardecchia et
al. [49] noted that differences in neuropsychological out-
come between ET PKU and controls had become
smaller at T2, but had not disappeared entirely. Further-
more, as expected, Phe levels increased with age and re-
sults suggest that ET AwPKU who had low childhood
Phe and those who had better metabolic control during
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adolescence had better cognitive outcomes in adulthood
[42, 49].
Discussion
Summary of findings
Cognitive functioning
Cognitive performance of ET AwPKU varied across the
different studies and cognitive domains included in this
review. In general, impairments in cognitive functioning
across domains tended to be observed more on mea-
sures of speed than accuracy. ET AwPKU were slower
when compared to healthy controls or normative data.
However, these speed deficits were rarely observed in
tasks of ‘pure’ processing speed (e.g. simple reaction
time), apart from in off-diet ET AwPKU [35, 38]. As
suggested by Romani et al. [17], these findings could in-
dicate that ET AwPKU may not suffer from a processing
speed deficit per se. Reductions in speed of performance
across multiple cognitive domains are more likely to be
the result of speed-accuracy trade-offs due to slower or
more cautious executive decision-making processes.
Compared to healthy controls and normative data, im-
pairments in cognitive performance of ET AwPKU have
been most consistently found on tasks of vigilance, WM
and motor skills. Furthermore, there is some evidence
for deficits in performance on tasks of attentional cap-
acity, verbal fluency, complex language skills, complex
EF and inhibitory control. For both complex EF and
WM tasks, deficits appear to be more pronounced on
tasks which have a higher cognitive load, i.e. requiring
more planning/reasoning and flexibility or WM, respect-
ively. Performance on tasks of simple processing speed,
memory, visual-spatial abilities, and simple language
processing does not seem to be impaired in ET AwPKU.
Social-cognitive abilities were reported to be affected in
ET AwPKU, but these abilities were only assessed in one
of the 15 studies included in this review. Finally, Jahja et
al. [42], Nardecha et al. [49] and Weglage et al. [52] re-
ported that overall cognitive performance remained
stable or improved over extended periods, despite an ob-
served increase in Phe. This could be due to adequate
adherence to treatment after childhood.
Impact of metabolic control on cognitive performance
Good versus poor metabolic control Several papers in-
cluded in this review explored differences in cognitive
performance between groups with high versus low levels
of Phe at the time of testing, often using different cri-
teria to discriminate the high- and low-Phe groups.
Some, but not all, of these studies reported that ET
AwPKU with low concurrent Phe levels outperformed
ET AwPKU with high concurrent Phe on tasks of se-
lective attention, memory and learning, and semantic
language skills. The majority of studies observed a
similar pattern for performance on sustained attention
tasks as well as motor skills. No differences in per-
formance on visual-spatial measures or measures of
complex EF were observed between groups of ET
AwPKU with high and low Phe levels at the time of test-
ing. Results from a few studies suggest that ET AwPKU
with high Phe levels at the time of testing may have worse
inhibitory control than those with low concurrent Phe
levels. Finally, some studies suggest that ET AwPKU with
high concurrent Phe and those with high childhood-Phe
levels are more at risk of developing WM impairments
compared to ET AwPKU with low concurrent or child-
hood Phe, respectively.
Associations with metabolic control throughout life
Associations between Phe levels and memory and learn-
ing, as well as motor skills, were observed across the
lifespan. The relationship appears more robust for visual
delayed and recognition memory than measures of ver-
bal memory. Language skills appear to be moderately
correlated with childhood Phe levels, which might reflect
the fact that language skills are developed during child-
hood [62]. In contrast, vigilance, complex EF, inhibition
and WM were most frequently reported to be correlated
with lifetime Phe and Phe later in life (concurrent Phe
and Phe during adolescence and adulthood). A possible
explanation for this is that these cognitive functions,
supported by the prefrontal cortex, are affected by
decreased levels of dopamine resulting from poor meta-
bolic control [63, 64]. Limited associations were ob-
served between verbal fluency and concurrent and
childhood Phe levels and no associations between Phe
and social-cognitive abilities and visual-perceptual abil-
ities were found. Furthermore, limited evidence suggests
fluctuations in Phe levels throughout life affect cognitive
performance of ET AwPKU. Finally, in studies reporting
relationships with Phe for outcome measures of speed
and accuracy separately, significant correlations were
generally more frequently observed with measures of
speed compared to measures of accuracy. Speed-specific
associations were predominantly observed with Phe earl-
ier in life (childhood and adolescent Phe). As suggested
by Romani et al. [46], speed deficits might be modulated
by structural myelin damage caused by suboptimal Phe
control early in life.
The vast majority of reported correlations were of
moderate strength (see Additional file 1: Table S1) and
in the expected direction, such that cognitive perform-
ance worsened with an increase in Phe.
Limitations/ methodological issues
Several factors may have contributed to inconsistent
findings across studies in ET AwPKU.
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Sample
Samples of ET AwPKU are highly heterogeneous: pa-
tients are likely to have different PAH-genotypes and will
have had varying degrees of dietary adherence through-
out life and at the time of testing, leading to inter and
intra-individual variability in Phe-levels. Furthermore,
some studies included mixed samples of on-diet and
off-diet ET AwPKU in the same analysis, whereas others
split samples based on their dietary management status.
However, no studies clearly defined what was meant by
‘off-diet’, and it is unclear whether the ET AwPKU in-
cluded followed an omnivorous diet, vegan or vegetarian
diet or whether they were still (unconsciously) limiting
their protein intake. ET AwPKU doing the latter might
suffer from nutritional deficiencies [65] that could affect
cognitive functioning (e.g. vitamin B12 [66, 67]) along-
side raised Phe. Moreover, although some authors stated
that their sample of ET AwPKU were continuously
treated, they report concurrent Phe-levels outside of tar-
get treatment ranges, suggesting that at least some of
their sample were not adherent to dietary recommenda-
tions at the time of testing. Therefore, the question re-
mains whether observed cognitive deficits are present in
ECT AwPKU. Future research would benefit from the
inclusion of additional nutritional measures to better
characterise the sample of ET AwPKU and explore the
impact of potential nutritional deficiencies on cognitive
outcomes. Moreover, to better evaluate the efficacy of
current treatments, research should focus on homoge-
neous samples, or, where this is not possible, include an
analysis of carefully characterised subgroups (e.g. on-diet
and off-diet).
The inconsistent findings in ET AwPKU in the studies
included in this review may be due to issues of sample
size. Because PKU is a rare disorder, it is difficult to re-
cruit and retain large samples. Generally, studies of PKU
tend to consist of small single centre studies, with a lim-
ited number of PKU patients living within study catch-
ment areas. Studies on cognitive performance in ET
AwPKU often include a relatively small (< 50 AwPKU)
number of participants [10] and are likely to be under-
powered. For example, Moyle et al. [35] observed no im-
pairments in cognitive functioning in 12 ET AwPKU
who discontinued their treatment during adolescence,
whereas Palermo et al. [11] and Jahja et al. [40] reported
several deficits in cognitive functioning in relatively well
controlled ET AwPKU (n = 37 and n = 57, respectively).
Research in PKU may benefit from more national and
international multi-centre collaborations, in order to
increase sample size to achieve sufficient power, and ad-
dress the need to recruit more homogeneous samples.
Furthermore, ET AwPKU who participate in research
are likely to be a self-selected sample who are more
engaged with their dietary management which could
positively bias findings. Deficits in cognitive functioning
are likely to be more prevalent and more severe in those
who are less adherent to their dietary management, but
these patients are likely to be underrepresented in the
literature. To illustrate, in the PKU COBESO study, only
21 of the original 68 ET PKU patients took part in the
long-term follow-up study [42]. Authors reported that at
initial testing, approximately 14 years earlier, this sub-
sample did not differ from controls on any of the cogni-
tive measures, whereas the sample as a whole showed
signs of cognitive impairments on several measures.
Furthermore, the patients who were lost to follow-up
had higher Phe levels at the time of initial testing. This
suggests that those patients who were retained for a sec-
ond test demonstrated better adherence to their dietary
management than the ET AwPKU who were lost to
follow-up. The percentage of participants who were lost
to follow-up in this research (69% of the original sample)
is similar to the percentage of AwPKU who were esti-
mated to not access regular clinical therapy in the
United States in 2013 (> 70%) [68], suggesting little is
known about cognitive functioning in the majority of ET
AwPKU. To our knowledge, only a few studies have
assessed cognitive performance in a group ET AwPKU
who discontinued their diet [35, 37, 38].
Cognitive performance testing
As is apparent from Table 2, the studies included in this
review used a wide variety of cognitive tests spanning a
range of cognitive domains and differing in sensitivity.
Besides sample size affecting the power of a study to de-
tect any cognitive deficits, cognitive tests differ in sensi-
tivity. This makes it difficult to compare outcome
measures from different studies and draw coherent con-
clusions. Furthermore, a number of the tests employed
in the studies do not necessarily test just one cognitive
domain, but rather recruit multiple cognitive functions
simultaneously. This can lead to discrepancies in the in-
terpretation of results. For example, the Stroop word
and colour subtests are regarded as language skills by
Palermo et al. [11] whereas others have reported Stroop
to be a measure of attention [33]. Additionally, because
they require planning a systematic search of the lexicon,
tests of verbal fluency are often believed to reflect EF
[69, 70]. However, as these tests tap into the lexicon, one
could also argue that performance primarily reflects lan-
guage skills [57]. In line with the framework used in this
review [53], the majority (3/4) of studies that included
tests of verbal fluency classified these as a measure of
EF. In addition to discrepancies in the interpretation of
cognitive test performance, there are also discrepancies
in the manner of reporting cognitive outcomes. Most
papers report outcomes of speed and accuracy separ-
ately, where possible. However, Romani et al. [46] used
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aggregated scores of cognitive performance on tests at-
tributed to a cognitive domain to explore the association
with metabolic control. Limitations of the use of aggre-
gated scores, even if well-constructed, are potential dif-
ferences in reliability and sensitivity of the individual
measures in relation to the construct (i.e. cognitive do-
main) that is being measured. [71]. Finally, only five of
the 22 publications included in this review reported ef-
fect sizes for their statistical test outcomes [35, 40–42,
44]. Effect sizes are crucial for the interpretation of ob-
served differences between groups. Even though p-values
indicate whether or not a significant difference exists,
they provide no information about the magnitude of the
difference [72]. Moyle et al. [35] reported large effect
sizes for observed deficits in cognitive performance in
off-diet ET AwPKU. In contrast, reported deficits in cog-
nitive functioning of ECT AwPKU in the PKU-COBESO
study were small [40]. However, observed improvements
in motor performance between T1 and T2 had medium
to large effect sizes [42]. Furthermore, Jahja et al. [42]
reported large effect sizes for differences in cognitive
performance between ECT AwPKU with good versus
poor metabolic control during childhood. Significant dif-
ferences in performance on cognitive tasks between ET
AwPKU and controls or normative or standardized data
should be interpreted with caution, especially when no
effect sizes have been reported. There is a need for
greater homogeneity amongst measurement tools and
the analysis and reporting of these in research in PKU.
Metabolic outcomes
Levels of metabolic control (i.e. Phe levels) at the time of
testing varied both between and within study samples. A
major contributor to such differences is the variation in
guidelines for the management of PKU between coun-
tries and sometimes even between clinics within the
same country. Furthermore, because guidelines have
changed throughout the life of the ET AwPKU included
in the research (e.g. diet for life is relatively recent advice
and was probably introduced after some ET AwPKU in-
cluded in the studies reviewed had already ceased the
diet). Time of diagnosis, onset of treatment, and meta-
bolic control throughout life are also likely to have var-
ied amongst participants. Moreover, it has been shown
that different methods for the analysis of dried blood
spots (DBS) as well as differences in the size of the
bloodspots that are measured could lead to significantly
different results [73, 74], and oversaturation or under-
saturation of the filter paper could lead to inaccurate re-
sults [74].
Research has also suggested that individuals with
PKU often change adherence to their dietary manage-
ment in the days leading up to a blood test, suggesting
measured levels of Phe may underrepresent typical Phe
levels [25, 75]. The large variance in Phe-data reported
and limitations of measures of metabolic control, com-
bined with relatively small sample sizes, reduces the
likelihood that observed correlations are reliable. As a
result of the variability in metabolic control between
participants, several studies created subgroups of ET
AwPKU with high or low Phe levels using different
cut-off criteria. In addition to using different cut-off
criteria to create subgroups for analysis, studies also
differed in how they reported measures of metabolic
control throughout life. Again, these discrepancies in
reporting make it difficult to compare study outcomes
and obtain a clear picture of how metabolic control
throughout life influences cognition in ET AwPKU.
Only a few of the studies included in this review ex-
plored the relationship between cognitive performance
and Phe variation throughout life [17, 46, 47] and these
found correlations across cognitive domains. More-
over, only one of the studies included measures of
Phe:Tyr ratio but did not explore the relationship be-
tween this outcome and cognitive performance [48].
Limited research on the association between Phe:Tyr
and EF in PKU suggests that high lifetime ratios rather
than average Phe levels were associated with observed
deficits in EF [76, 77]. It should be noted that Tyr
levels obtained via DBS could be inaccurate if patients
contaminate the filter paper by not washing their
hands prior to blood sampling. Future research should
include assessment of Phe fluctuations and Phe:Tyr
ratio throughout life to enable a better understanding
of the impact of metabolic control throughout life on
outcomes in adulthood. However, due to limitations in
measurements of metabolic control described previ-
ously, any observed associations should be interpreted
with caution.
Conclusions
Results from the studies included in this systematic re-
view suggest that, despite early treatment, ET AwPKU
have deficits in vigilance, WM, and motor skills com-
pared to healthy controls. Long-term cognitive outcomes
of ECT AwPKU remain unclear. Furthermore, several
associations between cognitive performance and meta-
bolic control throughout life were observed. However,
these findings were inconsistent and therefore, it is
difficult to determine the long-term effects of poor
metabolic control at different stages in life on cognitive
function in AwPKU.
To gain a better understanding of cognitive function-
ing and the development of cognitive deficits in ET
AwPKU and ECT AwPKU future research would benefit
from 1) (inter)national multicentre-studies; 2) more
homogeneous samples; and 3) the inclusion of other
nutritional measures that might influence cognitive
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functioning (e.g. Phe fluctuations, Phe:Tyr ratio and
micronutrients, such as vitamin B12) and 4) attention to
cognitive test selection and statistical analysis.
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